Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
Status:
Terminated
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study will assess the
- efficacy (response rate) of oral lenalidomide in the treatment of patients with
symptomatic, previously untreated, chronic lymphocytic leukemia (CLL),
- toxicity of lenalidomide in patients with CLL as well as time to progression, stable
disease duration and, if responses are observed, response duration.